{"id":122301,"date":"2021-07-19T19:45:00","date_gmt":"2021-07-19T19:45:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=28920242892024"},"modified":"2021-07-19T19:45:00","modified_gmt":"2021-07-19T19:45:00","slug":"the-vascular-disrupting-agents-market-is-projected-to-be-worth-usd-2-billion-by-2030-growing-at-an-annualized-rate-of-over-60-claims-roots-analysis","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/07\/19\/the-vascular-disrupting-agents-market-is-projected-to-be-worth-usd-2-billion-by-2030-growing-at-an-annualized-rate-of-over-60-claims-roots-analysis\/","title":{"rendered":"The vascular disrupting agents market is projected to be worth USD 2 billion by 2030, growing at an annualized rate of over 60%, claims Roots Analysis"},"content":{"rendered":"

\"\"<\/p>\n

Vascular disrupting agents (VDAs) are the novel oncology drugs being developed to more specifically combat complex, life threatening cancer indications<\/em><\/strong><\/p>\n

London<\/strong>\u00a0<\/strong><\/p>\n

Roots Analysis<\/strong><\/a> has announced the addition of \u201cVascular Disrupting Agents<\/strong><\/a> Market, 2021-2030<\/strong>\u201d report to its list of offerings.<\/p>\n

Despite multiple cancer treatment options, there is an evident unmet need for anti-cancer therapies with better efficacy and less toxicity. The vascular disrupting agents, which target the established tumor vasculature and disrupt blood flow to cancerous tissue, have garnered considerable interest as a novel anticancer therapeutic modality. \u00a0<\/p>\n

To order this 290+ page report, which features 110+ figures and 125+ tables, please visit <\/em><\/strong>https:\/\/www.rootsanalysis.com\/reports\/vascular-disrupting-agents-market.html<\/em><\/strong><\/a><\/p>\n

Key Market Insights <\/strong>\u00a0<\/strong><\/p>\n

Currently, more than 120 vascular disrupting agents are in the development pipeline<\/strong><\/p>\n

Around 50% of the vascular disrupting agents are being evaluated in phase II clinical trials, while more than 5% are either marketed or in phase III of development. Examples of phase III drugs include Bavituximab (non-small cell lung cancer), Icaritin (hepatocellular carcinoma), NGR-TNF (malignant pleural mesothelioma), Padeliporfin (transitional cell cancer of renal pelvis and ureter), Plinabulin (non-small cell lung cancer, chemotherapy-induced neutropenia) and VB-111 (glioblastoma, recurrent platinum resistant ovarian cancer). Further, 35% molecules are in phase I trials.<\/p>\n

Around 30 industry and non-industry players are engaged in the development of vascular disrupting agents<\/strong><\/p>\n

Around 40% of these firms are start-ups \/ small players (with less than 50 employees). It is also worth highlighting that, majority of the firms engaged in this domain (56%) are based in North America, followed by Asia Pacific (25%) and Europe (19%).<\/p>\n

Over 530 clinical trials are currently evaluating the therapeutic effects of vascular disrupting agents, worldwide <\/strong><\/p>\n

It is worth mentioning that most of the trials were \/ are being conducted in North America (56%), where more than 40% of the total number of patients had been enrolled. This is followed by clinical research activity in Europe (24%) and Asia Pacific (20%).<\/p>\n

Around 800 articles related to vascular disrupting agents have been published in reputed scientific journals, since 2016\u00a0 <\/strong><\/p>\n

More than 30% of the publications mentioned in the report, were focused on the assessment of treatment safety \/ effectiveness of various vascular disrupting agents. Popular journals that have published multiple articles related vascular disrupting agents, include Scientific Reports, Oncotarget, European Journal of Medicinal Chemistry, and PLoS One.<\/p>\n

Close to 220 grants have been awarded to support research on vascular disrupting agents, since 2016 <\/strong><\/p>\n

An estimated USD 96 million in grants have been awarded to various companies \/ organizations working in this domain, during time period between 2016 and January 2021. Almost 20% of the total grant amount was funded by the National Cancer Institute.<\/p>\n

Over 265 eminent scientists (identified as key opinion leaders (KOLs)) are involved in the clinical trials of vascular disrupting agents<\/strong><\/p>\n

Around 50% of these KOLs are associated with the organizations based in North America, followed by those in Asia Pacific (38%) and Europe (12%). Majority of these KOLs are currently affiliated to hospitals and medical centers.<\/p>\n

The market is anticipated to grow at a CAGR of over 60%, during the period 2021-2030 <\/strong><\/p>\n

Growth in this domain is anticipated to be driven by the drugs that are being developed for the treatment of non-small cell lung cancer. North America (primarily the US) and Europe are expected to capture around 50% of the market share by 2030, in terms of the sales-based revenues.<\/p>\n

To request a sample copy \/ brochure of this report, please visit <\/em><\/strong>https:\/\/www.rootsanalysis.com\/reports\/vascular-disrupting-agents-market\/request-sample.html<\/strong><\/a>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/em><\/strong><\/p>\n

Key Questions Answered<\/strong><\/p>\n